Denmark Introduces Early Dialogue With Procurement Agency For Expensive Medicines
Earlier dialogues would mean faster access to new medicines.
You may also be interested in...
The Scottish health technology appraisal body, the SMC, has announced its recommendations on Sanofi’s Dupixent, Ipsen’s Cabometyx, Sobi’s Zynlonta and Novartis’ Cosentyx.
A revised benefit rating for BMS’ cardiomyopathy drug Camzyos will be good news for the product’s pricing in Germany.
Mexico is to establish a new regulatory framework that is in line with international standards to encourage domestic production of biosimilar medicines.